Login / Signup

In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.

Bill H ChangKarina Thiel-KlareJeffrey W Tyner
Published in: bioRxiv : the preprint server for biology (2024)
Combining MEK and TNK2/SRC inhibitors has therapeutic potential in PTPN11 mutant JMML and AML.
Keyphrases
  • acute myeloid leukemia
  • tyrosine kinase
  • pi k akt
  • bone marrow
  • cancer therapy
  • allogeneic hematopoietic stem cell transplantation
  • wild type
  • cell proliferation
  • drug delivery